Comorbidity as a prognostic variable in multiple myeloma: Comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score

Blood Cancer Journal

Volumn 1, Issue 9, 2011, Pages

  Kleber, M ^a   Ihorst, G ^b   Terhorst, M ^a   Koch, B ^c   Deschler, B ^a   Wasch R ^a   Engelhardt, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Center of Clinical Trials   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Comorbidities; Comorbidity scores; Multiple myeloma; Prognosis

Indexed keywords

CREATININE; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; MELPHALAN; PREDNISONE; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COMORBIDITY; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEMATOPOIETIC CELL TRANSPLANTATION SPECIFIC COMORBIDITY; HUMAN; HYPERTENSION; KAPLAN FEINSTEIN AND SATARIANO INDEX; KARNOFSKY PERFORMANCE STATUS; KIDNEY DYSFUNCTION; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; PAIN; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT;

EID: 84856853048     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.34     Document Type: Article

References (45)

1. Denz U, Haas PS, Wasch R, Einsele H, Engelhardt M. State of the art therapy in multiple myeloma and future perspectives. Eur J Cancer 2006; 42: 1591-1600. (Pubitemid 44118774)
2. Engelhardt M, Mertelsmann R. 160 Years of multiple myeloma: progress and challenges. Eur J Cancer 2006; 42: 1507-1509. (Pubitemid 44118777)
3. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
4. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Riskadapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007; 82: 323-341. (Pubitemid 46348934)
5. Deschler B, Binek K, Ihorst G, Marks R, Wasch R, Bertz H et al. Prognostic factor and quality of life analysis in 160 patients aged 4 or=60 years with hematologic neoplasias treated with allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010; 16: 967-975.
6. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603. (Pubitemid 46291823)
7. Sperr WR, Wimazal F, Kundi M, Baumgartner C, Nosslinger T, Makrai A et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 2009; 21: 114-119.
8. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246-4254. (Pubitemid 47554249)
9. Etienne A, Esterni B, Charbonnier A, Mozziconacci MJ, Arnoulet C, Coso D et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer 2007; 109: 1376-1383. (Pubitemid 46466565)
10. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919. (Pubitemid 41510773)
11. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003; 56: 221-229. (Pubitemid 36513483)
12. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008; 22: 1485-1493.
13. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma 2007; 48: 337-341. (Pubitemid 46994883)
14. Kleber M, Cybulla M, Bauchmuller K, Ihorst G, Koch B, Engelhardt M. Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice. Ann Oncol 2007; 18: 950-958. (Pubitemid 47054095)
15. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483. (Pubitemid 43855050)
16. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100. (Pubitemid 41623371)
17. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976-4984.
18. Kleber M, Ihorst G, Deschler B, Jakob C, Liebisch P, Koch B et al. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol 2009; 83: 519-527.
19. Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23: 9219-9226.
20. Ludwig H, Bolejack V, Crowley J, Blade J, Miguel JS, Kyle RA et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010; 28: 1599-1605.
21. Wedding U, Rohrig B, Klippstein A, Pientka L, Hoffken K. Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol 2007; 133: 945-950. (Pubitemid 47561710)
22. Sorror ML. Comorbidities and hematopoietic cell transplantation outcomes. Hematology Am Soc Hematol Educ Program 2010; 2010: 237-247.
23. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
24. Markert A, Thierry V, Kleber M, Behrens M, Engelhardt M. Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment. Int J Cancer 2009; 124: 722-728.
25. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383. (Pubitemid 17055592)
26. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974; 27: 387-404.
27. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120: 104-110. (Pubitemid 24027550)
28. Hasskarl J, Ihorst G, De Pasquale D, Schrottner P, Zerweck A, Wasch R et al. Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myeloma. Leuk Lymphoma 2010; 52: 247-259.
29. Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 1992; 80: 733-737.
30. Gassmann W, Pralle H, Haferlach T, Pandurevic S, Graubner M, Schmitz N et al. Staging systems for multiple myeloma: a comparison. Br J Haematol 1985; 59: 703-711. (Pubitemid 15133663)
31. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
32. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250-4256.
33. Moro-Sibilot D, Aubert A, Diab S, Lantuejoul S, Fourneret P, Brambilla E et al. Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer. Eur Respir J 2005; 26: 480-486. (Pubitemid 41264213)
34. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 954-964.
35. Nosslinger T, Tuchler H, Germing U, Sperr WR, Krieger O, Haase D et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol 2009; 21: 120-125.
36. Fonseca R. Strategies for risk-adapted therapy in myeloma. Hematology Am Soc Hematol Educ Program 2007, 304-310.
37. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175-181.
38. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27-33. (Pubitemid 40873958)
39. Chien JW, Sullivan KM. Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility? Biol Blood Marrow Transplant 2009; 15: 447-453.
40. Labonte L, Iqbal T, Zaidi MA, McDiarmid SA, Huebsch LB, Tay J et al. Utility of comorbidity assessment in predicting transplantation- related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008; 14: 1039-1044.
41. Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 2009; 23: 1131-1138.
42. Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol 2008; 67: 124-132.
43. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003; 8: 541-552. (Pubitemid 37467370)
44. Firat S, Bousamra M, Gore E, Byhardt RW. Comorbidity and KPS are independent prognostic factors in stage I nonsmall- cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52: 1047-1057. (Pubitemid 34219026)
45. Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20: 494-502. (Pubitemid 34072534)